Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Revenue of Lexicon Pharmaceuticals, Inc. (LXRX)
Revenue in 2023 (TTM): $1.2 M
According to Lexicon Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $1.2 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Lexicon Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $1.2 M | $1.12 M | $-163,464,000 | $-177,119,000 | $-177,119,000 |
| 2022 | $139 K | $-288,000 | $-98,737,000 | $-101,944,000 | $-103,128,000 |
| 2021 | $298 K | $-54,748,000 | $-86,664,000 | $-87,758,000 | $-88,268,000 |
| 2020 | $24 M | $22.07 M | $-41,095,999 | $-58,574,000 | $-70,184,000 |
| 2019 | $322.07 M | $318.84 M | $173.74 M | $124.12 M | $130.13 M |
| 2018 | $63.21 M | $60.72 M | $-96,088,000 | $-120,548,000 | $-120,548,000 |
| 2017 | $90.34 M | $88.44 M | $-125,271,000 | $-141,711,000 | $-129,050,000 |
| 2016 | $83.34 M | $-80,636,000 | $-125,818,000 | $-141,429,000 | $-141,429,000 |
| 2015 | $130.01 M | $34.83 M | $11.72 M | $-4,682,000 | $-4,682,000 |
| 2014 | $22.85 M | $-66,425,000 | $-96,183,000 | $-100,364,000 | $-100,294,000 |
| 2013 | $2.22 M | $-87,460,000 | $-99,292,000 | $-104,126,000 | $-104,126,000 |
| 2012 | $1.09 M | $-81,485,000 | $-103,907,000 | $-110,211,000 | $-110,211,000 |
| 2011 | $1.85 M | $1.85 M | $-108,800,000 | $-116,215,000 | $-116,215,000 |
| 2010 | $4.91 M | $4.91 M | $-93,688,000 | $-101,801,000 | $-101,775,000 |
| 2009 | $10.7 M | $10.7 M | $-84,294,000 | $-93,419,000 | $-82,780,000 |
| 2008 | $32.32 M | $32.32 M | $-86,264,000 | $-96,884,000 | $-76,860,000 |
| 2007 | $50.12 M | $50.12 M | $-64,532,000 | $-71,233,000 | $-58,794,000 |
| 2006 | $72.8 M | $72.8 M | $-39,976,000 | $54.43 M | $-54,311,000 |
| 2005 | $75.68 M | $75.68 M | $-24,484,000 | $39.2 M | $-36,315,000 |
| 2004 | $61.74 M | $61.74 M | $-34,582,000 | $-46,150,000 | $-47,172,000 |
| 2003 | $42.84 M | $42.84 M | $-41,063,000 | $ | $-64,198,000 |
| 2002 | $35.2 M | $35.2 M | $-42,314,000 | $ | $-59,670,000 |
| 2001 | $305.58 M | $305.58 M | $-27,089,000 | $ | $-35,172,000 |
| 2000 | $14.46 M | $17.08 M | $-32,856,000 | $ | $-25,994,080 |
| 1999 | $4.7 M | $6.7 M | $-10,800,000 | $ | $-12,500,000 |